Christoph U. Correll, MD

Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany

JCP
Emerging Treatments in Schizophrenia
InfoPack

February 15, 2022

Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data...
, ,
JCP
Educational Activity

October 12, 2021

Can you recognize risk factors for tardive dyskinesia? Are you familiar with diagnostic criteria? Do you regularly assess patients for the condition? Are you knowledgeable about using new medications...
,
JCP
Managing Treatment-Resistant Schizophrenia
Academic Highlights

September 7, 2021

Two experts offer a refresher on predictors and identification of treatment-resistant schizophrenia. Drs Correll and Howes also review therapeutic strategies.
,
JCP
Academic Highlights

August 31, 2021

Experts offer a review of the fundamentals of diagnosing and treating tardive dyskinesia.
,
PCC
Case Report

August 5, 2021

Huntington’s disease is a progressive neurodegenerative disorder inheritable in an autosomal dominant fashion. Although not very common, psychosis can potentially precede the motor manifestation of the disease. Read this...
, ,
JCP
Review Article

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
, , , et al
JCP
Academic Highlights

June 30, 2020

In this journal CME activity, find experts' recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.
,
JCP
Letter to the Editor

June 16, 2020

Drs Kane and Correll reply to the letter "Depression as a Factor in Nonadherence in Schizophrenia" by Hirakawa and Ishii.
,
JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
ASCP Corner

April 28, 2020

Antipsychotic polypharmacy in schizophrenia is common, but is it supported by evidence? And why is there an apparent disconnect between efficacy and effectiveness? This ASCP Corner article considers those...
,
JCP
Educational Activity

April 14, 2020

Patient-reported outcomes are important for assessing the impact of schizophrenia and the success of treatment. Dr Correll discusses patient-centered care.
JCP
Educational Activity

April 14, 2020

New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Here, an expert summarizes data on approved and investigational agents.

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe